First-Line Letermovir Prophylaxis for Cytomegalovirus Prevention After Heart Transplantation: A Retrospective Single-Center Study (ISHLT 2026) - Feb 2, 2026 - Abstract #Pub #1275; Pres time: Apr 24, 2026; 04:30 PM - 05:30 PM; Location: Poster Hall; Board #418; "Although valganciclovir (VGCV) is the standard prophylactic agent, its use is often limited by hematologic toxicity...All patients received standard triple immunosuppression (Tac, mycophenolate mofetil, prednisone)...Letermovir was safe, well tolerated, and prevented clinically significant CMV infection without myelosuppression or renal impairment. These findings support its role as a first-line VGCV alternative, particularly for patients with cytopenia or renal dysfunction, warranting further multicenter validation."
Retrospective data • Cytomegalovirus Infection • Hematological Disorders • Nephrology • Neutropenia • Renal Disease • Transplantation
|
|
T. Sato; C. Ota; K. Nagatomo; G. Narita; H. Kawauchi; R. Shimomura; H. Mochizuki; T. Watanabe; S. Fukushima; C. Izumi; Y. Tsukamoto
|